Platelets Indices and Its Role to Predict Liver Fibrosis in Patients With Chronic Hepatitis B Infection
October 2, 2022 updated by: Wafaa Adel Abdelghany, Assiut University
Platelets indices and its role to predict liver Fibrosis in patients with chronic hepatitis B infection
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
Patients with chronic Hepatitis B infection will be collected and will do liver fibroscan to predict the degree of liver Fibrosis and correlate between the role of platelets count and degree of liver Fibrosis in patients with Chronic hepatitis B virus
Study Type
Observational
Enrollment (Anticipated)
75
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Wafaa Ad Abdelghany, resident DR
- Phone Number: 01118845248
- Email: wafaaadel789@gmail.com
Study Contact Backup
- Name: Osama AH Ibrahim
- Phone Number: 01202455792
- Email: oIbrahim@yahoo.com
Study Locations
-
-
-
Assiut, Egypt
- AssiutU
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 66 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
patients at Age from 18 to 70 years with chronic hepatits B infection will do liver fibroscan and correlate between platelets indicies and degree of liver fibrosis
-
Description
Inclusion Criteria:
- Age from 18 to 70 years
- without a history of clinical illness
Exclusion Criteria:
- with other hepatitis virus infection; (b) with alcoholic liver disease; (c) with any disease related to fibrosis (such as connective tissue diseases, chronic obstructive pulmonary disease, kidney failure, tumors, and so on); (d) have received any anti-fibrosis therapy; and (e) pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
75
patients with chronic hepatitis B infection will be collected and underwill liver fibroscan then corelate between platelets indicies and predict degree of liver fibrosis
|
Patients with CHB virus will do liver fibroscan and correlat between platelets count and degree of liver fibrosis
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Platelets indices and its role to predict liver Fibrosis in patients with chronic hepatitis B infection
Time Frame: Two years
|
Correlation between platelets count and degree of liver Fibrosis in patients with chronic hepatitis B virus through liver fibroscan
|
Two years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Ahmed AB Maghraby, Professor, Assiut University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Zhong LK, Zhang G, Luo SY, Yin W, Song HY. The value of platelet count in evaluating the degree of liver fibrosis in patients with chronic hepatitis B. J Clin Lab Anal. 2020 Jul;34(7):e23270. doi: 10.1002/jcla.23270. Epub 2020 May 4.
- Tan YW, Zhou XB, Ye Y, He C, Ge GH. Diagnostic value of FIB-4, aspartate aminotransferase-to-platelet ratio index and liver stiffness measurement in hepatitis B virus-infected patients with persistently normal alanine aminotransferase. World J Gastroenterol. 2017 Aug 21;23(31):5746-5754. doi: 10.3748/wjg.v23.i31.5746.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
October 20, 2022
Primary Completion (Anticipated)
August 15, 2023
Study Completion (Anticipated)
December 15, 2023
Study Registration Dates
First Submitted
October 2, 2022
First Submitted That Met QC Criteria
October 2, 2022
First Posted (Actual)
October 5, 2022
Study Record Updates
Last Update Posted (Actual)
October 5, 2022
Last Update Submitted That Met QC Criteria
October 2, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Platelets and liver fibrosis
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
the value of platelets count in evaluating the degree of liver fibrosis in patients with chronic hepatits B infecion
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.